Read
Seattle Genetics Launched the Phase II Clinical Trial of Antibody-drug Conjugate (ADC) Called Enfortumab Vedotin
Enfortumab vedotin is an experimental ADC drug linked by a monoclonal antibody targeting the nectin-4 protein and a microtubule disruptor vedotin (MMAE) via Seattle Genetics' proprietary conjugated technology.